PapersFlow Research Brief
Mycobacterium research and diagnosis
Research Guide
What is Mycobacterium research and diagnosis?
Mycobacterium research and diagnosis encompasses the study of Mycobacterium species, including Mycobacterium tuberculosis and nontuberculous mycobacteria, through genomic sequencing, molecular detection methods like real-time PCR and mNGS, antibiotic susceptibility testing, and clinical diagnostic criteria to identify and manage infections such as tuberculosis.
Research on Mycobacterium includes the complete genome sequence of Mycobacterium tuberculosis, which revealed 4,441 genes and provided insights into its biology (Cole et al., 1998, 'Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence'). Diagnostic approaches rely on methods like real-time RT-PCR for relative quantification of gene expression (Pfaffl, 2001, 'A new mathematical model for relative quantification in real-time RT-PCR') and standardized disk diffusion for antibiotic susceptibility (Bauer et al., 1966, 'Antibiotic Susceptibility Testing by a Standardized Single Disk Method'). The field comprises 127,251 works with growth data unavailable over the past 5 years.
Research Sub-Topics
Mycobacterium tuberculosis genome sequencing
This sub-topic covers whole genome sequencing of clinical MTB isolates to identify drug resistance mutations and transmission clusters. Researchers develop bioinformatics pipelines for variant calling and phylogenetic analysis.
Nontuberculous mycobacteria identification
This sub-topic examines molecular diagnostics using 16S/23S rRNA sequencing and MALDI-TOF for NTM species differentiation. Researchers validate assays against culture methods and correlate genotypes with clinical outcomes.
Real-time PCR for Mycobacterium detection
This sub-topic develops quantitative RT-PCR assays with internal controls for TB diagnosis in sputum and extrapulmonary samples. Researchers optimize primer design, validate analytical sensitivity, and assess clinical utility.
Mycobacterial antibiotic susceptibility testing
This sub-topic standardizes disk diffusion and broth microdilution methods for first- and second-line TB drugs. Researchers establish clinical breakpoints and evaluate phenotypic versus genotypic resistance correlation.
Latent tuberculosis infection diagnostics
This sub-topic evaluates IGRA assays and novel biomarkers for detecting LTBI in low-prevalence populations. Researchers conduct head-to-head trials comparing TST reversion rates and predictive value for progression.
Why It Matters
Mycobacterium research and diagnosis directly impacts tuberculosis control and management of nontuberculous mycobacterial diseases, with clinical guidelines specifying diagnostic criteria such as two positive cultures with compatible symptoms for pulmonary disease (Griffith et al., 2007, 'An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases'). Infliximab treatment increases tuberculosis risk, as 70 cases were linked to its use among 500,000 treated patients, emphasizing pre-treatment screening (Keane et al., 2001, 'Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent'). Recent preprints highlight point-of-care assays like fastNTM for direct identification of Mycobacterium tuberculosis complex and 8 nontuberculous mycobacteria in 149 clinical samples, and mNGS optimizations improving tuberculosis detection sensitivity.
Reading Guide
Where to Start
'Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence' by Cole et al. (1998), as it provides foundational genomic insights into Mycobacterium tuberculosis with 7787 citations, serving as an entry point before diagnostic papers.
Key Papers Explained
Cole et al. (1998, 'Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence') established the genomic basis, which Pfaffl (2001, 'A new mathematical model for relative quantification in real-time RT-PCR') built upon for molecular quantification tools applicable to Mycobacterium detection. Griffith et al. (2007, 'An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases') integrated these into clinical criteria (5942 citations), while Bauer et al. (1966, 'Antibiotic Susceptibility Testing by a Standardized Single Disk Method') provided enduring susceptibility testing standards (18152 citations) used alongside molecular methods.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on metagenomic next-generation sequencing (mNGS) comparisons with real-time PCR for Mycobacterium tuberculosis detection, multiplex point-of-care assays like fastNTM for 8 nontuberculous mycobacteria in clinical samples, and quantitative PCR for distinguishing MTB from NTM like Mycobacterium avium complex. News highlights rapid lab-in-tube assays for TB diagnosis from respiratory samples and self-powered T-cell response assays detecting OX-40/4-1BB markers.
Papers at a Glance
In the News
Rapid tuberculosis diagnosis from respiratory or blood samples by a low cost, portable lab-in-tube assay
Point-of-care diagnosis of*Mycobacterium tuberculosis*(*Mtb*), the pathogen that causes tuberculosis (TB), is a critical public health need. Here, Youngquist*et al*. developed a lab-in-tube assay p...
Self-powered rapid antigen-specific T-cell response assay for Mycobacterium tuberculosis infections
Here we describe the development and characterization of an antigen-specific T-cell response assay (ASTRA) that detects OX-40 and 4-1BB activation markers using a streamlined microchip-based proced...
New Test Detects TB in Less than 2 Hours
# New Test Detects TB in Less than 2 Hours
Development and evaluation of a multiplex molecular point-of-care assay for direct identification of Mycobacterium tuberculosis and prioritized non-tuberculous mycobacteria
**Objective:**This study aimed to establish a multiplex molecular point-of-care assay called*fastNTM*incorporating an ultra-fast sample pre-treatment for direct identification of*Mycobacterium tube...
June 2025 DMID Council-Approved Concepts | NIAID
## Partnerships for Development of Vaccines to Prevent _Mycobacterium tuberculosis_ Infection and/or Tuberculosis
Code & Tools
## About An nf-core (meta) pipeline for analysis of different members of Mycobacterium tuberculosis complex. nf-co.re/tbanalyzer ### Topics
## Repository files navigation # MycoID **My** cology species **Id** entification - Fungal Species Identification using Oxford Nanopore Technolog...
`TBtypeR` enables **accurate and sensitive quantification** of _Mycobacterium tuberculosis_ (MTB) strain mixtures from whole genome sequencing (WGS...
This repository contains a complete rewrite of the web version of TB-Profiler , described here . It allows the use of profiling through a command l...
MAGMA (**M**aximum**A**ccessible**G**enome for**M**tb**A**nalysis) is a pipeline for comprehensive genomic analyses of Mycobacterium tuberculosis w...
Recent Preprints
Comparison and evaluation of metagenomic next-generation sequencing (mNGS) and real-time PCR for the detection of Mycobacterium tuberculosis
**Objective:**This study aimed to evaluate and compare the performance of metagenomic next-generation sequencing (mNGS) and real-time polymerase chain reaction (RT-PCR) for the detection of*Mycobac...
Development and evaluation of a multiplex molecular point-of-care assay for direct identification of Mycobacterium tuberculosis and prioritized non-tuberculous mycobacteria
**Objective:**This study aimed to establish a multiplex molecular point-of-care assay called*fastNTM*incorporating an ultra-fast sample pre-treatment for direct identification of*Mycobacterium tube...
Clinical value of quantitative PCR in diagnosis of suspected mycobacterial pulmonary infections
Due to the difficulty in clinically distinguishing pulmonary infections caused by _Mycobacterium tuberculosis_ (MTB) and _Non-tuberculous mycobacteria_ (NTM), the study utilizes quantitative PCR (q...
Optimization of decision thresholds for Mycobacterium tuberculosis can effectively improve the performance of mNGS in tuberculosis diagnosis
**Background:** Pulmonary tuberculosis (TB) diagnosis remains challenging due to limitations in traditional methods. This study aimed to optimize the metagenomic next-generation sequencing (mNGS) t...
The relevance of biomarkers for diagnosis, monitoring treatment response and immunity during tuberculosis infections
protective immunity assessment. We review current developments in the molecular, immunological, transcriptomic, proteomic and metabolomic domains, including multi-gene signatures and microRNAs that...
Latest Developments
Recent developments in Mycobacterium research include a new test that accurately determines which antibiotics truly kill bacteria, improving treatment precision for tuberculosis and lung infections (ScienceDaily, published January 12, 2026). Additionally, advancements in diagnostic methods include the development of rapid molecular assays such as the all-in-one iFIND TBR for detecting Mycobacterium tuberculosis and rifampicin resistance, assessed in October 2024 (Frontiers). Furthermore, WHO released updated guidelines in April 2025 to improve TB diagnosis, including new recommendations on testing and detection technologies (WHO).
Sources
Frequently Asked Questions
What diagnostic criteria define nontuberculous mycobacterial lung disease?
Diagnosis requires compatible clinical symptoms, radiographic abnormalities, and two or more positive sputum cultures or one bronchial wash/lavage culture with compatible histology (Griffith et al., 2007, 'An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases'). Positive cultures must show moderate to many colonies to exclude contamination.
How does real-time RT-PCR quantify Mycobacterium gene expression?
Real-time RT-PCR amplifies cDNA from mRNA using a mathematical model for relative quantification, enabling accurate measurement of low-abundance transcripts (Pfaffl, 2001, 'A new mathematical model for relative quantification in real-time RT-PCR'). It provides reliable results through efficiency-corrected calculations.
What did the Mycobacterium tuberculosis genome sequence reveal?
The complete genome sequence of Mycobacterium tuberculosis strain H37Rv contains 4,411,481 base pairs and 4,441 predicted protein-coding genes, identifying unique features like PE/PPE gene families (Cole et al., 1998, 'Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence'). This enabled insights into persistence and pathogenicity mechanisms.
How is antibiotic susceptibility tested for Mycobacterium?
A standardized single disk method measures inhibition zone diameters around antibiotic disks on agar plates to classify bacteria as susceptible, intermediate, or resistant (Bauer et al., 1966, 'Antibiotic Susceptibility Testing by a Standardized Single Disk Method'). Zone interpretative standards are based on correlation with minimal inhibitory concentrations.
What role does 16S/23S rRNA sequencing play in Mycobacterium identification?
16S/23S rRNA sequencing identifies Mycobacterium species by analyzing conserved and variable regions in ribosomal RNA genes (Lane, 1991, '16S/23S rRNA sequencing'). It supports precise taxonomic classification in diagnostic settings.
Why screen for tuberculosis before infliximab therapy?
Infliximab, a TNF-α inhibitor, is associated with active tuberculosis development soon after initiation, with cases reported in screened and latent infection patients (Keane et al., 2001, 'Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent'). Screening detects latent infection to prevent reactivation.
Open Research Questions
- ? How can mNGS decision thresholds be optimized to improve sensitivity and specificity for Mycobacterium tuberculosis complex detection without increasing false positives?
- ? What biomarkers in molecular, proteomic, and metabolomic domains best distinguish latent from active tuberculosis and predict treatment response?
- ? How do multiplex point-of-care assays like fastNTM perform in direct clinical samples for simultaneous Mycobacterium tuberculosis and nontuberculous mycobacteria identification?
- ? What host immune defects and microbial interactions contribute to nontuberculous mycobacterial disease pathogenesis beyond known genetic factors?
- ? Can self-powered T-cell assays using OX-40 and 4-1BB markers reliably monitor Mycobacterium tuberculosis infection immunity in real-time?
Recent Trends
Preprints from the last 6 months emphasize metagenomic next-generation sequencing (mNGS) versus real-time PCR for Mycobacterium tuberculosis detection, with optimizations of mNGS thresholds improving pulmonary TB diagnosis performance.
Multiplex point-of-care assays like fastNTM enable direct identification of Mycobacterium tuberculosis complex and 8 nontuberculous mycobacteria in 149 clinical samples.
News reports portable lab-in-tube assays for rapid TB diagnosis from respiratory or blood samples and new tests detecting TB in under 2 hours.
Research Mycobacterium research and diagnosis with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Mycobacterium research and diagnosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.